Detalhe da pesquisa
1.
Differential Bile Acid Detection in Refractory GERD Patient Saliva Using a Simple and Sensitive Liquid Chromatography Tandem Mass Spectrometry Approach.
J Clin Gastroenterol
; 56(3): 218-223, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33731598
2.
sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH.
Proc Natl Acad Sci U S A
; 116(22): 11057-11062, 2019 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31085647
3.
IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial.
Gastroenterology
; 158(8): 2093-2103, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32092310
4.
The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system.
J Neuroinflammation
; 18(1): 213, 2021 Sep 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34537066
5.
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
Diabetologia
; 63(4): 733-743, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31858186
6.
Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure.
Am J Physiol Renal Physiol
; 318(1): F148-F159, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31608671
7.
Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells.
Am J Physiol Renal Physiol
; 319(4): F697-F711, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32865013
8.
Low-Dose Linaclotide (72 µg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Am J Gastroenterol
; 113(1): 105-114, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29091082
9.
Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.
J Pharmacol Exp Ther
; 365(3): 664-675, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29643251
10.
Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
J Gastroenterol Hepatol
; 33(5): 980-989, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29319191
11.
MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.
J Pharmacol Exp Ther
; 355(1): 48-56, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26216942
12.
Two randomized trials of linaclotide for chronic constipation.
N Engl J Med
; 365(6): 527-36, 2011 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-21830967
13.
Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
Clin Gastroenterol Hepatol
; 12(4): 616-23, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24075889
14.
Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
Gastroenterology
; 145(6): 1334-46.e1-11, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23958540
15.
Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
J Pharmacol Exp Ther
; 344(1): 196-206, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23090647
16.
Response to Miner et al.
Am J Gastroenterol
; 112(11): 1750-1751, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29109497
17.
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Am J Gastroenterol
; 107(11): 1702-12, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22986437
18.
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
Am J Gastroenterol
; 107(11): 1714-24; quiz p.1725, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22986440
19.
Efficacy of linaclotide for patients with chronic constipation.
Gastroenterology
; 138(3): 886-95.e1, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20045700
20.
Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
Gastroenterology
; 139(6): 1877-1886.e2, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20801122